E64d is an inhibitor of cathepsins that exhibits neuroprotective activity. In vivo, E64d inhibits cathepsin D, decreasing brain amyloid-β (Aβ) plaque formation. E64d inhibition of cathepsins also aggravates left ventricular dysfunction in animal models of myocardial infarction.
| Cas No. | 88321-09-9 |
|---|---|
| Purity | ≥97% |
| Formula | C17H30N2O5 |
| Formula Wt. | 342.43 |
| IUPAC Name | ethyl (2S,3S)-3-[[(2S)-4-methyl-1-(3-methylbutylamino)-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate |
| Synonym | Aloxistatin |
| Solubility | Soluble in ethanol (>10 mg/ml), DMSO (20 mg/ml), DMF (30 mg/ml), and 1:1 DMSO:PBS (pH 7.2) (~0.5 mg/ml). Insoluble in water. |
| Appearance | White Crystal Powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Hook G, Yu J, Toneff T, et al. Brain Pyroglutamate Amyloid-Beta is Produced by Cathepsin B and is Reduced by the Cysteine Protease Inhibitor E64d, Representing a Potential Alzheimer's Disease Therapeutic. J Alzheimers Dis. 2014 Mar 4. [Epub ahead of print]. PMID: 24595198.
Chen H, Wang J, Xiang MX, et al. Cathepsin S-mediated fibroblast trans-differentiation contributes to left ventricular remodelling after myocardial infarction. Cardiovasc Res. 2013 Oct 1;100(1):84-94. PMID: 23771947.
